FDA Approves Enspryng for Thyroid Eye Disease

Genentech’s satralizumab is the first IL-6 receptor inhibitor cleared for thyroid eye disease, and the only treatment patients can give themselves at home, though one of its two pivotal trials fell short.

On October 15, 2026, the FDA approved Genentech’s Enspryng (satralizumab) for adults with thyroid eye disease (TED), making it the first and only at-home subcutaneous treatment for the condition. It is also the first IL-6 receptor inhibitor cleared for TED, a disease that until now has been treated mainly with intravenous infusions.

Enspryng is not a new drug. The FDA first approved it in 2020 for neuromyelitis optica spectrum disorder (NMOSD), a rare autoimmune condition of the central nervous system. TED is its second approved use.

What Is Enspryng and How Does It Work?

Enspryng (satralizumab-mwge) is a humanized monoclonal antibody developed by Chugai, part of the Roche Group. It blocks the interleukin-6 (IL-6) receptor, shutting down a signaling pathway that drives the inflammation behind TED. The antibody uses a “recycling” technology that lets it bind its target over and over and stay in circulation longer, which is part of why it can be dosed as infrequently as once a month.

Patients start with loading doses at weeks zero, two, and four, then move to a maintenance injection every four weeks. After training from a clinician, a patient or caregiver can give the shot at home, into the abdomen or thigh, instead of coming in for an infusion.

How It Differs From Existing TED Treatments

Until recently, the main prescription option for active TED was Tepezza (teprotumumab), approved in 2020 and given as eight IV infusions spaced three weeks apart. Enspryng’s pitch is convenience: a subcutaneous shot patients can manage themselves, with far less time in an infusion chair. The two drugs were studied in separate trials and have not been compared head-to-head, so the approval adds an option rather than proving one is better than another.

What the Trials Showed

Approval rested on two identically designed Phase 3 studies, SatraGO-1 and SatraGO-2, which together enrolled 258 patients across 19 countries and randomized them 1:1 to Enspryng or placebo. The primary endpoint was the share of patients whose eye bulging (proptosis) improved by at least 2 mm at week 24.

The results were mixed. In SatraGO-2, 52.9% of patients with active TED responded on proptosis, versus 23.4% on placebo, and 60.7% saw their double vision (diplopia) improve, versus 25.8%. SatraGO-1, though, missed its primary endpoint: 49% of treated patients responded against 31.2% on placebo, a gap the investigators blamed on an unusually strong placebo response. Detailed results were presented at the ASOPRS Fall Scientific Symposium in October 2025, and the trial design was published in Ophthalmology and Therapy.

Safety and Side Effects

Genentech reported no new safety signals in the SatraGO trials, and the profile matched what has been seen in more than 16,000 patients treated for NMOSD. The most common side effects included nasopharyngitis (cold-like symptoms), rash, fatigue, headache, upper respiratory infections, and joint pain. The label warns about serious infections — patients are screened for hepatitis B and tuberculosis before starting — along with elevated liver enzymes, low neutrophil counts, and allergic reactions.

Why Enspryng Matters for TED Patients

Thyroid eye disease, also called Graves’ ophthalmopathy, is an autoimmune condition that inflames the muscles and tissue around the eyes. It affects roughly 155 of every 100,000 people and is closely tied to Graves’ disease and an overactive thyroid. Symptoms run from redness, swelling, and eyelid retraction to the hallmark bulging eyes and double vision, which can be painful and, in severe cases, threaten sight.

“As the first subcutaneous treatment for this condition, Enspryng offers a positive safety and efficacy profile and the potential for at-home administration,” said Levi Garraway, M.D., Ph.D., Genentech’s chief medical officer.

For patients, the appeal is flexibility. “The approval of Enspryng represents a critical turning point through a convenient, targeted option,” said Christine Gustafson, CEO of the TED Community Organization. César Briceño, M.D., an ophthalmologist at the University of Pennsylvania's Scheie Eye Institute who worked on the trials, said an effective injectable “could provide greater flexibility for both patients and physicians.”